FDA Approves Eye Drops Offering Potential Relief from Presbyopia
The Food and Drug Administration today approved Vizz, a new eye drop treatment offering a non-surgical option for presbyopia, the age-related loss of near vision affecting millions.
Vizz, which contains pilocarpine – a medication previously used for glaucoma since the 1970s – works by constricting the pupil to increase depth of focus, improving close-up vision without impacting distance sight. Scientists discovered the unexpected benefit during patient observation and subsequently conducted years of testing to confirm its efficacy for presbyopia. The treatment requires one drop in each eye daily and provides relief for approximately 10 hours, at a cost of roughly $2 per day.
Early trials have shown promising results, with some users reporting significant improvement in near vision within minutes of application. “In just ten minutes I could read effortlessly,” stated Dr. Joseph Varon, a physician who initially approached the treatment with skepticism. While mild stinging or tearing may occur, specialists emphasize the drops should only be used under a doctor’s prescription and are not recommended for nighttime use by individuals with advanced glaucoma or other serious eye conditions. Presbyopia is a common condition, impacting an estimated 119 million Americans by 2030, according to the American Academy of Ophthalmology.
The approval of Vizz represents a significant advancement in vision correction, potentially reducing reliance on reading glasses or more invasive procedures like laser surgery. Further research is underway to develop eye drops that can dynamically adjust focus based on distance, building on this breakthrough. The FDA continues to monitor the drug’s performance and encourages patients to discuss any concerns with their healthcare provider, as detailed in the FDA’s official statement.
